# US 2026/0027156 A1 · Bispecific chimeric antigen receptors targeting bcma and cd19

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0027156 A1
- Document ID: US20260027156A1
- Status: Published application
- Kind: A1
- Application number: 19/351,823
- Filed: 2025-10-07
- Published: 2026-01-29
- Earliest claimed: 2023-04-11
- Assignees: Abelzeta Inc.
- Applicants: Abelzeta Inc.
- Inventors: Yihong YAO; Jiaqi HUANG; Shigui ZHU; Xin YAO; Xiaobing LUO; Yanfeng LI
- Web page: https://patentgrep.com/patent/US20260027156A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61P 35/00: Antineoplastic agents
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C12N 5/0636: {T lymphocytes}
- A61K 2239/13: Antibody-based
- A61K 2239/17: Hinge-spacer domain
- A61K 2239/21: Transmembrane domain
- A61K 2239/29: Multispecific CARs
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/31: multispecific
- C07K 2317/53: Hinge
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides bispecific chimeric antigen receptors targeting BCMA and CD19. The CAR may comprise an scFv targeting BCMA and an scFv targeting CD19, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.

## Claims

### Claim 1

A bispecific chimeric antigen receptor (CAR), comprising:
(i) an anti-BCMA antigen-binding region which comprises a light chain variable region (VL1) and a heavy chain variable region (VH1), wherein VL1 comprises three complementarity determining regions (CDRs), CDR1, CDR2 and CDR3, having amino acid sequences about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, respectively, and wherein VH1 comprises three CDRs, CDR1, CDR2 and CDR3, having amino acid sequences about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, respectively; and
(ii) an anti-CD19 antigen-binding region which comprises a light chain variable region (VL2) and a heavy chain variable region (VH2), wherein VL2 comprises three complementarity determining regions (CDRs), CDR1, CDR2 and CDR3, having amino acid sequences about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, respectively, and wherein VH2 comprises three CDRs, CDR1, CDR2 and CDR3, having amino acid sequences about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, respectively.

### Claim 2 (depends on 1)

The bispecific CAR of claim 1, wherein VL1 is located at the N-terminus of VH1.

### Claim 3 (depends on 1)

The bispecific CAR of claim 1, wherein VL2 is located at the N-terminus of VH2.

### Claim 4 (depends on 1)

The bispecific CAR of claim 1, wherein VH1 is located at the N-terminus of VLI.

### Claim 5 (depends on 1)

The bispecific CAR of claim 1, wherein VH2 is located at the N-terminus of VL2.

### Claim 6 (depends on 1)

The bispecific CAR of claim 1, wherein VL1 and VH1 have amino acid sequences about 80% to about 100% identical to amino acid sequences set forth in SEQ ID NO: 24 and SEQ ID NO: 28, respectively.

### Claim 7 (depends on 1)

The bispecific CAR of claim 1, wherein VL2 and VH2 have amino acid sequences about 80% to about 100% identical to amino acid sequences set forth in SEQ ID NO: 32 and SEQ ID NO: 36, respectively.

### Claim 8 (depends on 1)

The bispecific CAR of claim 1, wherein the anti-BCMA antigen-binding region is a single-chain variable fragment (scFv) that specifically binds BCMA, and wherein the anti-CD19 antigen-binding region is a scFv that specifically binds CD19.

### Claim 9 (depends on 1)

The bispecific CAR of claim 1, wherein the bispecific CAR further comprises one or more of the following:
(a) a signal peptide,
(b) a hinge region,
(c) a transmembrane domain,
(d) a co-stimulatory region, and
(e) a cytoplasmic signaling domain.

### Claim 10 (depends on 9)

The bispecific CAR of claim 9, wherein the co-stimulatory region comprises a co-stimulatory region of 4-1BB (CD137), CD28, OX40, CD2, CD7, CD27, CD30, CD40, CD70, CD134, PD1, Dap10, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), NKG2D, GITR, TLR2, or combinations thereof.

### Claim 11 (depends on 9)

The bispecific CAR of claim 9, wherein the cytoplasmic signaling domain comprises a cytoplasmic signaling domain of CD3ζ.

### Claim 12 (depends on 9)

The bispecific CAR of claim 9, wherein the hinge region comprises a hinge region of IgG4, CD8, CD28, CD137, or combinations thereof.

### Claim 13 (depends on 9)

The bispecific CAR of claim 9, wherein the transmembrane domain comprises a transmembrane domain of CD8, CD28, CD3ε, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, or combinations thereof.

### Claim 14 (depends on 9)

The bispecific CAR of claim 9, comprising an amino acid sequence about 80% to about 100% identical to the amino acid sequence set forth in SEQ ID NO:46, SEQ ID NO:60, SEQ ID NO:74, SEQ ID NO:88, SEQ ID NO:104, SEQ ID NO:121, SEQ ID NO:138, or SEQ ID NO:155.

### Claim 15 (depends on 1)

An immune cell expressing the bispecific CAR of claim 1.

### Claim 16 (depends on 15)

The immune cell of claim 15, wherein the immune cell is a T cell or a natural killer (NK) cell.

### Claim 17 (depends on 1)

A nucleic acid encoding the bispecific CAR of claim 1.

### Claim 18 (depends on 15)

A method of treating an autoimmune disorder, the method comprising administering the immune cell of claim 15 to a subject in need thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the autoimmune disorder is systemic lupus erythematosus (SLE), systemic sclerosis, inflammatory myopathy, systemic scleroderma, multiple sclerosis, myasthenia gravis, a myositis autoantibody-driven disease, or neuromyelitis optica.

### Claim 20 (depends on 19)

The method of claim 19, wherein the inflammatory myopathy is polymyositis, dermatomyositis, or inclusion-body myositis.

### Claim 21 (depends on 19)

The method of claim 19, wherein the subject has lupus nephritis.

### Claim 22 (depends on 18)

The method of claim 18, wherein the immune cell is allogeneic or autologous.
